Suppr超能文献

一种无需使用次黄嘌呤氨基蝶呤胸腺嘧啶核苷(HAT)培养基来培育人T-T细胞杂交体的新方法。

A new method for the development of human T-T cell hybrids without the use of HAT medium.

作者信息

Platsoucas C D, Calvelli T A, Kunicka J A

机构信息

Department of Immunology, M.D. Anderson Hospital and Tumor Institute, Houston, TX 77030.

出版信息

Hybridoma. 1987 Dec;6(6):589-603. doi: 10.1089/hyb.1987.6.589.

Abstract

We report here a new method for the development of human T-T cell hybrids by fusing mitogen- or alloantigen-stimulated T cells with non-mutagenized cells from human lymphoblastoid T cell lines. This method is based on a new selection procedure where the hybrids are separated from the parent T cell line on the basis of their ability to form colonies in soft agar. In contrast, cells from lymphoblastoid T cell lines Molt-4 and Jurkat do not form colonies in agar. Hybridoma colonies are retrieved from the agar plates, expanded in culture, screened by HLA-typing and appropriate functional tests and recloned several times by limiting dilution. HAT medium, which contains thymidine that appears to be toxic to the hybrids, is not used in our selection procedure. Using this method, we developed human T-T cell hybridomas (as determined by HLA-typing) producing B-cell growth factor (BCGF) either constitutively or after induction with Concanavalin A (Con A). Certain other T-T cell hybrids produced suppressor factor, significantly inhibiting proliferative responses of human peripheral blood mononuclear leukocytes to PHA, Con A and allogeneic cells in mixed lymphocyte culture.

摘要

我们在此报告一种通过将丝裂原或同种异体抗原刺激的T细胞与人淋巴母细胞T细胞系的未诱变细胞融合来开发人T-T细胞杂交瘤的新方法。该方法基于一种新的筛选程序,即根据杂交瘤在软琼脂中形成集落的能力将其与亲本T细胞系分离。相比之下,来自淋巴母细胞T细胞系Molt-4和Jurkat的细胞在琼脂中不形成集落。从琼脂平板上获取杂交瘤集落,在培养中扩增,通过HLA分型和适当的功能测试进行筛选,并通过有限稀释法多次克隆。我们的筛选程序不使用含有对杂交瘤似乎有毒的胸腺嘧啶核苷的HAT培养基。使用这种方法,我们开发了人T-T细胞杂交瘤(通过HLA分型确定),它们组成性地或在用刀豆球蛋白A(Con A)诱导后产生B细胞生长因子(BCGF)。某些其他T-T细胞杂交瘤产生抑制因子,显著抑制人外周血单个核白细胞对PHA、Con A和混合淋巴细胞培养中的同种异体细胞的增殖反应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验